Predicted vs. Observed 3-Year Mortality in the ALT FLOW Early Feasibility Study Cohort

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; American Regent; Amgen; Applied Therapeutic,; AstraZenca; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb; Cardiac Dimension; CVRx; Cardior; Cytokinetics; Daxor Edwards,; Element Science; Impluse Dynamics; Inventiva; Lexicon; Lilly; Imbria; LivaNova; Janssen Pharmaceuticals; Medtronics; Merck/Schering Plough; Occlutech; Owkin; novartis; Pfizer; Novo Nordisk; Pharmacosmos; Pharmain; Prolaio; Roche; Secretome; Sequana; SQ Innovation; Tenex; Vifor</li><li>Grant Support/Research Contract - Innolife</li></ul>